EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma

The EphA3 receptor has recently emerged as a functional tumour-specific therapeutic target in glioblastoma (GBM). EphA3 is significantly elevated in recurrent disease, is most highly expressed on glioma stem cells (GSCs), and has a functional role in maintaining self-renewal and tumourigenesis. An u...

Full description

Bibliographic Details
Main Authors: Carolin Offenhäuser, Fares Al-Ejeh, Simon Puttick, Kathleen S. Ensbey, Zara C. Bruce, Paul R. Jamieson, Fiona M. Smith, Brett W. Stringer, Benjamin Carrington, Adrian V. Fuchs, Craig A. Bell, Rosalind Jeffree, Stephen Rose, Kristofer J. Thurecht, Andrew W. Boyd, Bryan W. Day
Format: Article
Language:English
Published: MDPI AG 2018-12-01
Series:Cancers
Subjects:
EphA3
antibody drug conjugate
radioimmunotherapy
glioblastoma
stem cells
Online Access:https://www.mdpi.com/2072-6694/10/12/519

Internet

https://www.mdpi.com/2072-6694/10/12/519

Similar Items